Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel

(2016) Sayaka Sobue et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Selumetinib in the treatment of non-small-cell lung cancer

(2016) Reyes Bernabé et al.   Future Oncology

SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway

(2016) Weipeng Zhang et al.   JOURNAL OF DRUG TARGETING

The challenge of screening for early gastric cancer in China

(2016) Liang Zong et al.   LANCET

Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform

(2016) Y. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation

(2016) Mark Borris D. Aldonza et al.   Oncotarget

Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – A critical role of Cdk1 in mitotic entry

(2015) Wei-Ling Chang et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules

(2015) Yu Yu et al.   CANCER CELL

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer

(2015) Zhi Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs

(2015) Youngmi Kim et al.   MOLECULES AND CELLS

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells

(2015) Chihuei Wang et al.   PLoS One

Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells

(2015) Mark Borris Docdoc Aldonza et al.   PLoS One

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia

(2015) Jacky Wong et al.   Oncotarget

Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer

(2014) Jingwei Yu et al.   EUROPEAN JOURNAL OF CANCER

The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma

(2014) J. Gong et al.   ONCOLOGIST

Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers

(2013) Ju-yeon Jeong et al.   APOPTOSIS

Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells

(2013) Yunwei Ou et al.   CANCER BIOLOGY & THERAPY

Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy

(2013) Serena Giovinazzi et al.   CELL CYCLE

A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma

(2013) Lin Shen et al.   Journal of Cancer Research and Therapeutics

Management of gastric cancer in Asia: resource-stratified guidelines

(2013) Lin Shen et al.   LANCET ONCOLOGY

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer

(2012) Jianan Shen et al.   BIOMATERIALS

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

(2012) Jingwei Yu et al.   MEDICAL ONCOLOGY

A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells

(2011) Hong Qiu et al.   CANCER LETTERS

Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin

(2011) Ming Lu et al.   Chinese Journal of Cancer Research

mTOR as a therapeutic target in patients with gastric cancer

(2011) Salah-Eddin Al-Batran et al.   INTERNATIONAL JOURNAL OF CANCER

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

(2010) Y.-j. Mi et al.   CANCER RESEARCH

Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest

(2010) Margaret E Harley et al.   EMBO JOURNAL

Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of  III-Tubulin

(2010) P. P. Gan et al.   MOLECULAR CANCER THERAPEUTICS

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION